Showing 2101-2110 of 3039 results for "".
- Alcon Launches Clareon IOL Portfolio in the UShttps://modernod.com/news/alcon-launches-clareon-iol-portfolio-in-the-us/2480677/Alcon announced the launch of the Clareon family of IOLs in the United States. Utilizing an advanced IOL material, Clareon is designed to deliver consistent visual outcomes and clarity that lasts.[1-7] The Clareon clarity is born out of a glistening-free IOL material that has among
- Nicox Announces Vyzulta Now Commercialized in 7 Territories and Approved in Further 9 Countrieshttps://modernod.com/news/nicox-announces-vyzulta-now-commercialized-in-7-territories-and-approved-in-further-9-countries/2480660/Nicox provided an update on the approvals and launches of Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%, exclusively licensed worldwide by Nicox to Bausch + Lomb. “Vyzulta is the first product based on our nitric oxide-donating research platform which has bee
- Santen Launches Eyecare Education Learning Portal for Ophthalmologists in Europehttps://modernod.com/news/santen-launches-eyecare-education-learning-portal-for-ophthalmologists-in-europe/2480651/Santen announced
- Study Shows Significant Impact of Novel Omega-3 and Omega-6 Supplement for People with Severe Dry Eye Diseasehttps://modernod.com/news/study-shows-significant-impact-of-novel-omega-3-and-omega-6-supplement-for-people-with-severe-dry-eye-disease/2480627/A newly-published study conducted by the
- Aramis Biosciences Receives FDA Clearance to Proceed with Phase 2 Trail of A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aramis-biosciences-receives-fda-clearance-to-proceed-with-phase-2-trail-of-a197-a-novel-immunomodulatory-agent-for-the-treatment-of-dry-eye-disease/2480558/Aramis Biosciences announced that the FDA has cleared the investigational new drug (IND) application for A197, enabling the company to proceed with a phase 2 proof of concept clinical trial. “We are pleased that FDA has cleared A197 to move into phase 2 clinica
- Alcon Completes Acquisition of Ivantis, Bringing Hydrus Microstent into Its Global Surgical Portfoliohttps://modernod.com/news/alcon-completes-acquisition-of-ivantis-bringing-hydrus-microstent-into-its-global-surgical-portfolio/2480555/Alcon announced the closing of its previously announced acquisition of Ivantis, developer of the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surge
- Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseaseshttps://modernod.com/news/ray-therapeutics-closes-6m-seed-financing-to-advance-novel-optogenetics-platform-to-treat-blinding-diseases/2480549/Ray Therapeutics, a developer of optogenetic gene therapies for patients with blinding diseases, announced the closing of a $6 million seed financing round, led by 4BIO Capital. The funding will be used to advance its optogenetic therapy, Ray-001, into clinical trials in retinitis
- Rayner Expands RayOne Portfolio with Company's First Blue Light Filtering IOLhttps://modernod.com/news/rayner-expands-rayone-portfolio-with-companys-first-blue-light-filtering-iol/2480548/Rayner announced the launch of the RayOne Hydrophobic BLF, Rayner’s first blue
- Prevent Blindness Issues Call for Nominations for 2022 National Awardshttps://modernod.com/news/prevent-blindness-issues-call-for-nominations-for-2022-national-awards/2480547/
- Harrow Health Acquires US Commercial Rights to Four Branded Eye Drops from Novartishttps://modernod.com/news/harrow-health-imprimisrx-acquires-us-commercial-rights-to-four-branded-eye-drops-from-novartis/2480527/Harrow Health, the parent company of ImprimisRx, announced its has acquired the exclusive US commercialization rights of four FDA-approved ophthalmic medicines—Iopidine 1% and 0.5% (apraclonidine hydroc